Canada markets closed

Mauna Kea Technologies SA (MKEAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
At close: 08:44AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.4000
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4000 - 1.4000
52 Week Range1.3300 - 2.0500
Volume1,000
Avg. Volume0
Market Cap58.675M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.4720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Mauna Kea Technologies Announces its 2022 Financial Calendar

    PARIS & BOSTON, January 24, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of its 2022 Financial Calendar.

  • Business Wire

    Mauna Kea Technologies Reports Fourth Quarter and Full Year 2021 Sales

    PARIS & BOSTON, January 20, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced fourth quarter and full year 2021 sales.

  • Business Wire

    Mauna Kea Technologies Provides Business Update

    PARIS & BOSTON, January 13, 2022--Regulatory News: Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a board-approved plan designed to reduce operating expenses and maximize capital resources in order to support the Company's strategic focus on the use of Cellvizio as an aid for real-time characterization of lung cancer and for molecular imaging g